180 related articles for article (PubMed ID: 34572958)
1. Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study.
Lombardi G; Caccese M; Padovan M; Cerretti G; Pintacuda G; Manara R; Di Sarra F; Zagonel V
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572958
[TBL] [Abstract][Full Text] [Related]
2. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
Caccese M; Desideri I; Villani V; Simonelli M; Buglione M; Chiesa S; Franceschi E; Gaviani P; Stasi I; Caserta C; Brugnara S; Lolli I; Bennicelli E; Bini P; Cuccu AS; Scoccianti S; Padovan M; Gori S; Bonetti A; Giordano P; Pellerino A; Gregucci F; Riva N; Cinieri S; Internò V; Santoni M; Pernice G; Dealis C; Stievano L; Paiar F; Magni G; De Salvo GL; Zagonel V; Lombardi G
ESMO Open; 2024 Apr; 9(4):102943. PubMed ID: 38492275
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity of regorafenib in elderly patients with recurrent glioblastoma.
Fasano M; Pirozzi M; Famiglietti V; Facchini S; Caterino M; Caroprese M; Barillaro A; Di Giovanni I; Auriemma A; Ileana Sara Fattoruso S; Somma T; Solari D; Bocchetti M; Conson M; Pacelli R; Ciardiello F; Addeo R
Mol Clin Oncol; 2023 Feb; 18(2):9. PubMed ID: 36761386
[TBL] [Abstract][Full Text] [Related]
5. Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?
Rudà R; Bruno F; Pellerino A; Pronello E; Palmiero R; Bertero L; Crasto S; Polo V; Vitaliani R; Trincia E; Internò V; Porta C; Soffietti R
J Neurooncol; 2022 Nov; 160(2):389-402. PubMed ID: 36309895
[TBL] [Abstract][Full Text] [Related]
6. Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).
Padovan M; Eoli M; Pellerino A; Rizzato S; Caserta C; Simonelli M; Michiara M; Caccese M; Anghileri E; Cerretti G; Rudà R; Zagonel V; Lombardi G
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204877
[TBL] [Abstract][Full Text] [Related]
7. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas.
Werner JM; Wolf L; Tscherpel C; Bauer EK; Wollring M; Ceccon G; Deckert M; Brunn A; Pappesch R; Goldbrunner R; Fink GR; Galldiks N
J Neurooncol; 2022 Sep; 159(2):309-317. PubMed ID: 35716310
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
Lombardi G; Del Bianco P; Brandes AA; Eoli M; Rudà R; Ibrahim T; Lolli I; Rizzato S; Daniele B; Pace A; Pasqualetti F; Caccesse M; Bergo E; Magni G; De Salvo GL; Zagonel V
Eur J Cancer; 2021 Sep; 155():179-190. PubMed ID: 34388515
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
13. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Solms A; Reinecke I; Fiala-Buskies S; Keunecke A; Drenth HJ; Bruix J; Meinhardt G; Cleton A; Ploeger B
Eur J Pharm Sci; 2017 Nov; 109S():S149-S153. PubMed ID: 28549676
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.
Zeiner PS; Kinzig M; Divé I; Maurer GD; Filipski K; Harter PN; Senft C; Bähr O; Hattingen E; Steinbach JP; Sörgel F; Voss M; Steidl E; Ronellenfitsch MW
J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31766326
[TBL] [Abstract][Full Text] [Related]
15. Reirradiation with radiosurgery or stereotactic fractionated radiotherapy in association with regorafenib in recurrent glioblastoma.
Gregucci F; Di Guglielmo FC; Surgo A; Carbonara R; Laera L; Ciliberti MP; Gentile MA; Calbi R; Caliandro M; Sasso N; Davi' V; Bonaparte I; Fanelli V; Giraldi D; Tortora R; Internò V; Giuliani F; Surico G; Signorelli F; Lombardi G; Fiorentino A
Strahlenther Onkol; 2023 Nov; ():. PubMed ID: 37987802
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
